Answers are grounded in this paper and cite their sources.
Quantitative structure–activity relationship (QSAR) modelling connects the chemical structure of compounds described using values to their biological effects how the body handles them or their harmful properties. This review looks at how QSAR has changed since the 1960s starting with the Hansch and Free–Wilson methods and how it has grown into today's use of machine learning. It covers the types of molecular descriptors the modelling techniques used validation practices and how QSAR helps in designing new drugs. The review is based on peer-reviewed studies found in PubMed, Scopus, Web of Science and Google Scholar with attention to guidelines from the OECD and recent improvements in the field. Traditional 2D and 3D-QSAR methods like CoMFA and CoMSIA are still useful especially when working with compounds and when understanding the science behind the results is important. For more varied datasets modern methods such as random forests support vector machines, deep neural networks and graph neural networks show better performance.. Success doesn't come just from using advanced algorithms. The reliability of a QSAR model depends a lot on how well the data is cleaned and prepared how it is tested using both internal and external validation whether y-randomisation is done and how clearly the models applicability domain is defined. QSAR plays a role in many areas of drug development. It is used in screening to find promising compounds in optimizing lead molecules in predicting absorption, distribution, metabolism, excretion and toxicity (ADMET) and in predicting harmful effects. It has also helped in discovering antibiotics like halicin using artificial intelligence. Despite its usefulness QSAR still faces some problems. These include inconsistent data, activity cliffs where small changes lead to big differences in activity, limited understanding of model decisions and the need to estimate uncertainty and do prospective testing. Looking ahead progress will come from AI that makes models easier to understand from transfer learning and multi-task learning that allow models to use knowledge from different tasks and, from combining QSAR with structure-based methods and system-level approaches. Together these advances help keep QSAR as an cost-effective part of modern drug design.
No takes yet. Share an insight, caveat, or question.
D. et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: